The GVAX/PCa vaccine is classified as a genetically modified cancer cell vaccine, utilizing the LNCaP and PC-3 cell lines to produce and secrete granulocyte–macrophage colony-stimulating factor (GM-CSF) [32,33]. The gene discussed is CSF2; the disease is posterior cortical atrophy.